Corbus Pharmaceuticals Holdings (STU:3371) Total Receivables: €0.00 Mil (As of Mar. 2026)


STU:3371 Corbus Pharmaceuticals Holdings Inc STU:3371
31 GF Score
Price €8.45
GF Value €0.40
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings Total Receivables?

Corbus Pharmaceuticals Holdings STU:3371 +0.36% 31 Total Receivables is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:3371 with a GF Score™ of 31/100 and a GF Value™ of €0.40 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Corbus Pharmaceuticals Holdings's Total Receivables for the quarter that ended in Mar. 2026 was €0.00 Mil.

Corbus Pharmaceuticals Holdings Total Receivables Related Terms

Corbus Pharmaceuticals Holdings Total Receivables Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings Total Receivables Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Corbus Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:3371
31GF Score
Corbus Pharmaceuticals Holdings Inc STU:3371
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.00 Mil mean?
Corbus Pharmaceuticals Holdings (STU:3371) has a Total Receivables of €0.00 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Corbus Pharmaceuticals Holdings and its competitors.
Is Corbus Pharmaceuticals Holdings' Total Receivables too high?
Corbus Pharmaceuticals Holdings' current Total Receivables is €0.00 Mil. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Total Receivables compare to PRQR and NRXP?
Corbus Pharmaceuticals Holdings' Total Receivables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Corbus Pharmaceuticals Holdings and its competitors. Corbus Pharmaceuticals Holdings's current Total Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings (STU:3371) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.40, compared to a current price of €8.45 — trading 2012.5% above its estimated fair value. The current Total Receivables is €0.00 Mil. Corbus Pharmaceuticals Holdings' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (STU:3371), the current Total Receivables is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corbus Pharmaceuticals Holdings (STU:3371) Overvalued in 2026?

Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings stock appears to be overvalued. The current stock price of €8.45 is trading 2012.5% above its estimated GF Value™ of €0.40. GuruFocus considers Corbus Pharmaceuticals Holdings to be Significantly Overvalued.

Key valuation signals for STU:3371:

  • Total Receivables: €0.00 Mil
  • GF Value™: €0.40 vs. price of €8.45 (2012.5% above fair value)
  • GF Score™: 31/100 with 1 warning sign

No single metric tells the full story. See the STU:3371 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA0SZI:UK
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
31GF Score

Get the complete analysis for STU:3371

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.45
Price
€0.40
GF Value